First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. Background: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback